DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pharmaceutical Industry in China" report to their offering.
Aruvian's R'search's report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc.
The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry.
Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, This latest research is a collection of all you need to know about China's Pharmaceutical Industry.
The Chinese pharmaceuticals market is forecast to become the world's firth largest by 2010 - and the largest by 2050. There are still greater market access following China's entry into the World Trade Organization (WTO), multinational investors continue to face a range of obstacles, many of which stem from the legacy of central planning of the industry. These include complex distribution, under-developed retail options, intellectual property infringements and pricing controls and pressures. At the same time, the continuing reliance of leading domestic companies on generic drugs has prevented the emergence of Chinese brands.
Key Topics Covered:
A. Executive Summary
B. The Global Pharmaceutical Industry - A Brief Profile
C. China Pharmaceutical Industry
D. OTC Pharmaceuticals in China
E. Generics Sector in China
F. Market Trends & Growth Opportunities
G. Regulatory Developments & Framework
H. China Pharmaceutical Industry - SWOT Framework Analysis
I. China Pharmaceutical Industry - PEST Framework Analysis
J. China Pharmaceutical Industry - Porter's Five Forces Business Strategy Analysis
K. Evolving Strategic Options for Chinese Companies
L. Impact of Changing IP Laws on Product Level Access to Medicines in China
M. Investment Options in China's Pharmaceutical Industry
N. China's WTO Accession - Challenges & Opportunities
O. Contract Research Services in China's Pharma Sector
P. China's Pharmaceutical Industry - Future Perspective
Q. Major Industry Players
- Q.1 AstraZeneca PLC
- Q.2 Bayer AG
- Q.3 Beijing Double-Crane Pharmaceutical (DCPC)
- Q.4 Beijing TongRenTang Co., Ltd.
- Q.5 GlaxoSmithKline Plc
- Q.6 Guilin Sanjin Pharmaceutical Co., Ltd.
- Q.7 Northeast Pharmaceutical Group (NEPG)
- Q.8 Novartis AG
- Q.9 Pfizer Inc
- Q.10 Roche Holding AG
- Q.11 Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL)
- Q.12 Shanghai Pharmaceutical (Group) Co. Ltd (SPCL)
- Q.13 STADA Arzneimittel
- Q.14 Wuhan Grand Pharmaceutical
- Q.15 Yunnan Baiyao Group Co., Ltd.
For more information visit Research and Markets
